In basal-like primary and metastatic tumors, those tumors with HLA-A alterations had significantly higher numbers of MHC class I-associated neoantigens, which was not driven by a higher tumor mutational burden (TMB; Fig. 4g); in particular, participant AER2 showed more than 50 times higher neoantigen load in primary tumors and liver metastases than observed in other participants. The gene discussed is HLA-A; the disease is metastatic neoplasm.